RGEN

Repligen Corporation

RGEN, USA

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

https://www.repligen.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RGEN
stock
RGEN

RGEN's Price Target Raised by Barclays to $200 Amidst Overweight Rating | RGEN Stock News GuruFocus

Read more →
RGEN
stock
RGEN

RGEN: Wells Fargo Raises Repligen's Price Target to $190 | RGEN Stock News GuruFocus

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$187.5556

Analyst Picks

Strong Buy

10

Buy

4

Hold

5

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

8,251.00

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

4.27

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

0.72 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

0.51 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

22.62 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.40

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 92.89% of the total shares of Repligen Corporation

1.

T. Rowe Price Associates, Inc.

(11.7388%)

since

2025/06/30

2.

BlackRock Inc

(10.8046%)

since

2025/06/30

3.

Vanguard Group Inc

(9.0249%)

since

2025/06/30

4.

Point72 Asset Management, L.P.

(3.4008%)

since

2025/06/30

5.

iShares Core S&P Mid-Cap ETF

(3.0231%)

since

2025/08/31

6.

Vanguard Total Stock Mkt Idx Inv

(2.9826%)

since

2025/07/31

7.

State Street Corp

(2.8843%)

since

2025/06/30

8.

FMR Inc

(2.8677%)

since

2025/06/30

9.

Champlain Investment Partners, LLC

(2.4905%)

since

2025/06/30

10.

Amvescap Plc.

(2.4514%)

since

2025/06/30

11.

Bank of New York Mellon Corp

(2.3548%)

since

2025/06/30

12.

Vanguard Small Cap Index

(2.3028%)

since

2025/07/31

13.

Sands Capital Management, LLC

(2.2239%)

since

2025/06/30

14.

US Small-Cap Growth II Equity Comp

(2.1879%)

since

2025/06/30

15.

T. Rowe Price New Horizons

(2.1842%)

since

2025/07/31

16.

Sands Capital Global Growth Equity

(2.0217%)

since

2025/06/30

17.

Citadel Advisors Llc

(1.8896%)

since

2025/06/30

18.

Brown Capital Management, LLC

(1.7869%)

since

2025/06/30

19.

Geode Capital Management, LLC

(1.7433%)

since

2025/06/30

20.

Conestoga Capital Advisors, LLC

(1.7365%)

since

2025/06/30

21.

Holocene Advisors, LP

(1.6652%)

since

2025/06/30

22.

AllianceBernstein L.P.

(1.6111%)

since

2025/06/30

23.

Dimensional Fund Advisors, Inc.

(1.3652%)

since

2025/06/30

24.

Impax Asset Management Group PLC

(1.3528%)

since

2025/06/30

25.

Vanguard Small Cap Growth Index Inv

(1.2981%)

since

2025/07/31

26.

Millennium Management LLC

(1.2465%)

since

2025/06/30

27.

Champlain Mid Cap Fund, LLC

(1.2434%)

since

2025/08/31

28.

T. Rowe Price All-Cap Opportunities Fund

(1.1322%)

since

2025/07/31

29.

New York State Common Retirement Fund

(1.0773%)

since

2025/06/30

30.

T. Rowe Price US All-Cap Opp Eq Comp

(1.035%)

since

2025/06/30

31.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9989%)

since

2025/07/31

32.

Fidelity Select Medical Tech and Devcs

(0.8621%)

since

2025/07/31

33.

Conestoga Small Cap Investors

(0.8563%)

since

2025/07/31

34.

T. Rowe Price Glb Focused Growth Equity

(0.8539%)

since

2025/06/30

35.

Champlain Small Company Fund, LLC

(0.7965%)

since

2025/08/31

36.

SPDR® S&P MIDCAP 400 ETF Trust

(0.7114%)

since

2025/07/31

37.

T. Rowe Price New Horizons Tr-A

(0.7007%)

since

2025/06/30

38.

Impax Specialists Strategy Composite

(0.6914%)

since

2025/07/31

39.

Franklin US Small-Mid Cap Growth Equity

(0.6736%)

since

2025/06/30

40.

Fidelity Select Health Care

(0.6221%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0.46

EPS Estimate

0.4137

EPS Difference

0.0463

Surprise Percent

11.1917%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(6.8)
GARP
Fair GARP(4.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(5.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.